Molecular Partners AG (MOLN)
NASDAQ: MOLN · Real-Time Price · USD
4.230
-0.110 (-2.53%)
At close: Dec 26, 2025, 4:00 PM EST
4.350
+0.120 (2.84%)
After-hours: Dec 26, 2025, 4:10 PM EST
Molecular Partners AG Employees
Molecular Partners AG had 159 employees as of December 31, 2024. The number of employees decreased by 9 or -5.37% compared to the previous year.
Employees
159
Change (1Y)
-9
Growth (1Y)
-5.37%
Revenue / Employee
n/a
Profits / Employee
-$476,592
Market Cap
162.28M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 159 | -9 | -5.37% |
| Dec 31, 2023 | 168 | -8 | -4.45% |
| Dec 31, 2022 | 175 | 12 | 7.41% |
| Dec 31, 2021 | 163 | 18 | 12.24% |
| Dec 31, 2020 | 145 | 10 | 7.54% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MOLN News
- 9 days ago - Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 19 days ago - Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting - GlobeNewsWire
- 6 weeks ago - Molecular Partners AG (MOLN) Discusses First Human Imaging Data and Clinical Plans for MP0712 Radiotherapy Program Transcript - Seeking Alpha
- 6 weeks ago - Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action - GlobeNewsWire
- 7 weeks ago - Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025 - GlobeNewsWire
- 7 weeks ago - Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting - GlobeNewsWire
- 2 months ago - Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025 - GlobeNewsWire
- 4 months ago - EHang, Molecular Partners And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga